Compugen’s (CGEN) “Buy” Rating Reiterated at FBR & Co
Compugen Ltd. (NASDAQ:CGEN)‘s stock had its “buy” rating reaffirmed by equities research analysts at FBR & Co in a report issued on Tuesday.
Separately, Zacks Investment Research cut Compugen from a “buy” rating to a “hold” rating in a research report on Thursday, November 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $10.40.
Shares of Compugen (NASDAQ:CGEN) traded up 3.686% during midday trading on Tuesday, reaching $6.273. The company’s stock had a trading volume of 51,206 shares. The stock’s market capitalization is $319.47 million. The stock’s 50-day moving average is $6.13 and its 200 day moving average is $6.58. Compugen has a 12 month low of $4.32 and a 12 month high of $7.79.
Compugen (NASDAQ:CGEN) last issued its earnings results on Monday, November 7th. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. Compugen had a negative return on equity of 29.33% and a negative net margin of 261.77%. On average, analysts expect that Compugen will post ($0.61) earnings per share for the current fiscal year.
Several hedge funds have recently made changes to their positions in CGEN. Stockman Asset Management bought a new stake in shares of Compugen during the third quarter worth $597,000. Vanguard Group Inc. boosted its stake in shares of Compugen by 12.4% in the second quarter. Vanguard Group Inc. now owns 740,047 shares of the company’s stock worth $4,796,000 after buying an additional 81,729 shares in the last quarter. Vident Investment Advisory LLC bought a new stake in shares of Compugen during the second quarter worth $522,000. BlackRock Fund Advisors boosted its stake in shares of Compugen by 4.6% in the third quarter. BlackRock Fund Advisors now owns 671,557 shares of the company’s stock worth $4,231,000 after buying an additional 29,402 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. bought a new stake in shares of Compugen during the second quarter worth $164,000. 17.25% of the stock is owned by institutional investors.
Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.
Receive News & Stock Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related stocks with our FREE daily email newsletter.